4-氨基-吲唑-6-甲酸 | 885519-89-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 4-氨基-吲唑-6-甲酸
• 英文名称: 4-Amino-1H-indazole-6-carboxylic acid
• CAS: 885519-89-1
• 化学式: C₈H₇N₃O₂
• mdl: MFCD07781688
• 分子量: 177.16
• InChiKey: SJKLPWJKFWGTCT-UHFFFAOYSA-N

物化性质

• 沸点：
  549.3±35.0 °C(Predicted)
• 密度：
  1.611

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  92
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P330,P362,P403+P233,P501
• 危险性描述：
  H302,H312,H332

反应信息

• 作为产物：
  描述：

  4-氨基-吲唑-6-甲酸甲酯 在 水 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 以23.40 %的产率得到4-氨基-吲唑-6-甲酸
  参考文献：
  名称：

  NOVEL COMPOUNDS AS CK2 INHIBITORS

  摘要：

  Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: wherein RL, L and RR, and any groups associated therewith, are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.

  公开号：

  WO2024052702A1

文献信息

• NOVEL COMPOUNDS AS CK2 INHIBITORS
  申请人：[en]CAMBRIDGE ENTERPRISE LIMITED

  公开号：WO2024052702A1

  公开（公告）日：2024-03-14

  Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: wherein RL, L and RR, and any groups associated therewith, are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.